Egetis Therapeutics
ISIN: SE0003815604 | Ticker: EGTX | LEI: 549300RZCKGWRUBPMY22
Country: Sweden
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.
2006
HeadquartersKlara Norra Kyrkogata 26, 11122 Stockholm – Sweden
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | N/A | 569,300,000.00 | 561,100,000.00 |
| Noncurrent Assets | N/A | 416,400,000.00 | 413,700,000.00 |
| Licences And Franchises | N/A | 6,500,000.00 | 5,400,000.00 |
| Other Noncurrent Financial Assets | N/A | 800,000.00 | 800,000.00 |
| Current Assets | N/A | 152,900,000.00 | 147,400,000.00 |
| Inventories | N/A | 700,000.00 | 600,000.00 |
| Current Trade Receivables | N/A | 3,500,000.00 | 3,800,000.00 |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | 1,400,000.00 | 8,900,000.00 |
| Other Current Receivables | N/A | 3,300,000.00 | 6,400,000.00 |
| Cash and cash equivalents | 287,900,000.00 | 144,000,000.00 | 127,700,000.00 |
| Equity And Liabilities | N/A | 569,300,000.00 | 561,100,000.00 |
| Equity | 630,700,000.00 | 527,000,000.00 | 506,200,000.00 |
| Issued Capital | N/A | 8,700,000.00 | 11,300,000.00 |
| Retained Earnings | N/A | -745,800,000.00 | -939,600,000.00 |
| Other Reserves | N/A | 1,300,000.00 | 6,100,000.00 |
| Additional Paidin Capital | N/A | 1,262,800,000.00 | 1,428,400,000.00 |
| Noncurrent Liabilities | N/A | 3,100,000.00 | 5,500,000.00 |
| Noncurrent Payables On Social Security And Taxes Other Than Income Tax | N/A | 400,000.00 | 4,400,000.00 |
| Other Noncurrent Liabilities | N/A | 2,700,000.00 | 1,100,000.00 |
| Current Liabilities | N/A | 39,200,000.00 | 49,400,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 4,600,000.00 | 20,000,000.00 |
| Other Current Liabilities | N/A | 17,200,000.00 | 5,700,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 38,200,000.00 | 22,600,000.00 |
| Other Income | 300,000.00 | 0.00 |
| Employee Benefits Expense | 30,100,000.00 | 52,000,000.00 |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 2,500,000.00 | 2,700,000.00 |
| Other Expense By Nature | 14,500,000.00 | 22,300,000.00 |
| Profit Loss From Operating Activities | -105,700,000.00 | -198,100,000.00 |
| Finance Income | 1,300,000.00 | 5,000,000.00 |
| Finance Costs | 200,000.00 | 700,000.00 |
| Profit Loss Before Tax | -104,500,000.00 | -193,800,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 |
| Profit (loss) | -104,500,000.00 | -193,800,000.00 |
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | -104,500,000.00 | -193,800,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | -28,300,000.00 | 10,900,000.00 |
| Other Adjustments For Noncash Items | N/A | 2,700,000.00 | 9,400,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | -28,300,000.00 | 10,900,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 0.00 | 100,000.00 |
| Interest Received Classified As Operating Activities | N/A | 100,000.00 | 900,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -130,100,000.00 | -173,500,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 5,000,000.00 | 1,700,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 200,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -6,000,000.00 | -1,700,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 177,400,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 7,500,000.00 | 7,500,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,400,000.00 | 1,600,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -8,900,000.00 | 155,700,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -145,000,000.00 | -19,500,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 1,100,000.00 | 3,200,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -145,000,000.00 | -19,500,000.00 |
| Cash and cash equivalents | 287,900,000.00 | 144,000,000.00 | 127,700,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 07.07.23 | Henrik Krook | Other | Buy | SEK 133,704.12 |
| 06.07.23 | Christian Sonesson | Other | Buy | SEK 14,391.68 |
| 06.07.23 | Christian Sonesson | Other | Buy | SEK 7,920.00 |
| 05.07.23 | Christian Sonesson | Other | Buy | SEK 5,452.96 |
| 04.07.23 | Nicklas Westerholm | Other | Buy | SEK 60,632.50 |
| 05.06.23 | Elisabeth Svanberg | Other | Buy | SEK 54,586.80 |
| 01.06.23 | Kristina Sjöblom Nygren | Other | Buy | SEK 24,650.00 |
| 31.05.23 | Mats Blom | Other | Buy | SEK 991,600.00 |
| 20.06.22 | Henrik Krook | Other | Buy | SEK 281,176.69 |
| 20.06.22 | Henrik Krook | Other | Sell | SEK 274,291.77 |
SE0003815604
LEI549300RZCKGWRUBPMY22
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.